%0 Journal Article
%T Gene expression profiling of alveolar soft-part sarcoma (ASPS)
%A Luke H Stockwin
%A David T Vistica
%A Susan Kenney
%A David S Schrump
%A Donna O Butcher
%A Mark Raffeld
%A Robert H Shoemaker
%J BMC Cancer
%D 2009
%I BioMed Central
%R 10.1186/1471-2407-9-22
%X For seven patients with confirmed primary or metastatic ASPS, RNA samples were isolated immediately following surgery, reverse transcribed to cDNA and each sample hybridized to duplicate high-density human U133 plus 2.0 microarrays. Array data was then analyzed relative to arrays hybridized to universal RNA to generate an unbiased transcriptome. Subsequent gene ontology analysis was used to identify transcripts with therapeutic or diagnostic potential. A subset of the most interesting genes was then validated using quantitative RT-PCR and immunohistochemistry.Analysis of patient array data versus universal RNA identified elevated expression of transcripts related to angiogenesis (ANGPTL2, HIF-1 alpha, MDK, c-MET, VEGF, TIMP-2), cell proliferation (PRL, IGFBP1, NTSR2, PCSK1), metastasis (ADAM9, ECM1, POSTN) and steroid biosynthesis (CYP17A1 and STS). A number of muscle-restricted transcripts (ITGB1BP3/MIBP, MYF5, MYF6 and TRIM63) were also identified, strengthening the case for a muscle cell progenitor as the origin of disease. Transcript differentials were validated using real-time PCR and subsequent immunohistochemical analysis confirmed protein expression for several of the most interesting changes (MDK, c-MET, VEGF, POSTN, CYP17A1, ITGB1BP3/MIBP and TRIM63).Results from this first comprehensive study of ASPS gene expression identifies several targets involved in angiogenesis, metastasis and myogenic differentiation. These efforts represent the first step towards defining the cellular origin, pathogenesis and effective treatment strategies for this atypical malignancy.Alveolar soft-part sarcoma (ASPS) is an extremely rare (1 diagnosis per 10 million population per year) soft tissue sarcoma with an indolent course and generally poor prognosis [1-3]. The disease manifests in young adults (15¨C35 years), where it is usually diagnosed from a painless mass in the lower limbs, head or neck [1,4]. ASPS is surprisingly slow growing with a clinical course averaging 15 years
%U http://www.biomedcentral.com/1471-2407/9/22